Leadership Team
Meet our experienced team.
Our CTO, Dr Louise Duffy, Sr. Director of Bioconjugation Chemistry, Dr Nicolas Camper and Principal scientist, Dr Richard Spears will all be on hand at the event. You can also connect with our business development team, Patrick Haddad, Gildas Lavenant, and Roger Bowie.
In addition to exhibiting, we will be presenting the following talks and posters:
Day 1 Presentation on the Discovery Stream: “ThioBridge® – a Tool for the Design, Optimization & Manufacture of ADCs,” Speaker: Principal Scientist, Dr Richard Spears
Key topics covered:
Day 2 Presentation on the Manufacturing & Supply Chain Stream: “Strategies and Considerations for Successfully Scaling up Your ADC,” Speaker: CTO, Dr Louise Duffy
Abstract:
There is significant diversity in the design of an ADC, including the antibody, linkers, conjugation chemistries and drug, which makes the process for scaling up even more complex. Being aware of the challenges from the outset can help to mitigate risk when it comes time to scale-up and manufacture an antibody-drug conjugate. From understanding the functionalization of the antibody, to the conjugation reaction and downstream purification and formulation, all these stages play a critical part in ensuring the downstream success and delivery of your ADC.
Key topics covered:
Posters: